Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2011 (2011), Article ID 404929, 9 pages
http://dx.doi.org/10.1155/2011/404929
Research Article

Anti-IL-6 Receptor Antibody Causes Less Promotion of Tuberculosis Infection than Anti-TNF- 𝛼 Antibody in Mice

1Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka 591-8555, Japan
2Chugai Pharmaceutical Co., Ltd., Product Research Department, Shizuoka 412-8513, Japan
3Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Osaka 565-0871, Japan

Received 15 October 2010; Revised 24 December 2010; Accepted 28 January 2011

Academic Editor: Hiroshi Nakajima

Copyright © 2011 Masaji Okada et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Maini, E. W. St Clair, F. Breedveld et al., “Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial,” Lancet, vol. 354, no. 9194, pp. 1932–1939, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. P. E. Lipsky, D. M. F. M. van der Heijde, E. W. St. Clair et al., “Infliximab and methotrexate in the treatment of rheumatoid arthritis,” New England Journal of Medicine, vol. 343, no. 22, pp. 1594–1602, 2000. View at Publisher · View at Google Scholar
  3. J. M. Bathon, R. W. Martin, R. M. Fleischmann et al., “A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis,” New England Journal of Medicine, vol. 343, no. 22, pp. 1586–1593, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Nishimoto, J. Hashimoto, N. Miyasaka et al., “Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab,” Annals of the Rheumatic Diseases, vol. 66, no. 9, pp. 1162–1167, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. J. S. Smolen, A. Beaulieu, A. Rubbert-Roth et al., “Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial,” Lancet, vol. 371, no. 9617, pp. 987–997, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. Y. Ohsugi and T. Kishimoto, “The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis,” Expert Opinion on Biological Therapy, vol. 8, no. 5, pp. 669–681, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. Keane, S. Gershon, R. P. Wise et al., “Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent,” New England Journal of Medicine, vol. 345, no. 15, pp. 1098–1104, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. J. Gómez-Reino, L. Carmona, V. Rodríguez Valverde, E. M. Mola, and M. D. Montero, “Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report,” Arthritis and Rheumatism, vol. 48, no. 8, pp. 2122–2127, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. T. Botha and B. Ryffel, “Reactivation of latent tuberculosis infection in TNF-deficient mice,” Journal of Immunology, vol. 171, no. 6, pp. 3110–3118, 2003. View at Google Scholar · View at Scopus
  10. S. Ehlers, “Why does tumor necrosis factor targeted therapy reactivate tuberculosis?” Journal of Rheumatology, vol. 32, no. 74, pp. 35–39, 2005. View at Google Scholar · View at Scopus
  11. J. L. Flynn, M. M. Goldstein, J. Chan et al., “Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice,” Immunity, vol. 2, no. 6, pp. 561–572, 1995. View at Google Scholar · View at Scopus
  12. R. F. van Vollenhoven, N. Nishimoto, H. Yamanaka et al., “Experience with Mycobacterium tuberculosis infection reported in the tocilizumab worldwide RA safety database,” Annals of the Rheumatic Diseases, vol. 68, supplement 3, article 557, 2009. View at Google Scholar
  13. I. S. Leal, M. Flórido, P. Andersen, and R. Appelberg, “Interleukin-6 regulates the phenotype of the immune response to a tuberculosis subunit vaccine,” Immunology, vol. 103, no. 3, pp. 375–381, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. C. H. Ladel, C. Blum, A. Dreher, K. Reifenberg, M. Kopf, and S. H. E. Kaufmann, “Lethal tuberculosis in interleukin-6-deficient mutant mice,” Infection and Immunity, vol. 65, no. 11, pp. 4843–4849, 1997. View at Google Scholar · View at Scopus
  15. R. Appelberg, A. G. Castro, J. Pedrosa, and P. Minoprio, “Role of interleukin-6 in the induction of protective T cells during mycobacterial infections in mice,” Immunology, vol. 82, no. 3, pp. 361–364, 1994. View at Google Scholar · View at Scopus
  16. N. Yamaguchi, S. Ohshima, M. Umeshita-Sasai et al., “Synergistic effect on the attenuation of collagen induced arthritis in tumor necrosis factor receptor I (TNFRI) and interleukin 6 double knockout mice,” Journal of Rheumatology, vol. 30, no. 1, pp. 22–27, 2003. View at Google Scholar · View at Scopus
  17. T. Tamura, N. Udagawa, N. Takahashi et al., “Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 24, pp. 11924–11928, 1993. View at Publisher · View at Google Scholar · View at Scopus
  18. K. C. F. Sheehan, N. H. Ruddle, and R. D. Schreiber, “Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors,” Journal of Immunology, vol. 142, no. 11, pp. 3884–3893, 1989. View at Google Scholar · View at Scopus
  19. S. Yoshida, T. Tanaka, Y. Kita et al., “DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation,” Vaccine, vol. 24, no. 8, pp. 1191–1204, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. K. Miki, T. Nagata, T. Tanaka et al., “Induction of protective cellular immunity against Mycobacterium tuberculosis by recombinant attenuated self-destructing Listeria monocytogenes strains harboring eukaryotic expression plasmids for antigen 85 complex and MPB/MPT51,” Infection and Immunity, vol. 72, no. 4, pp. 2014–2021, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. R. O. Williams, M. Feldmann, and R. N. Maini, “Anti-tumor necrosis factor ameliorates joint disease in murine collagen- induced arthritis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 20, pp. 9784–9788, 1992. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Yoshida, M. Hashizume, M. Suzuki, and M. Mihara, “Induction of high-dose tolerance to the rat anti-mouse IL-6 receptor antibody in NZB/NZW F1 mice,” Rheumatology International. In press. View at Publisher · View at Google Scholar · View at PubMed
  23. C. C. Dascher, K. Hiromatsu, X. Xiong et al., “Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis,” International Immunology, vol. 15, no. 8, pp. 915–925, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Mihara, M. Shiina, N. Nishimoto, K. Yoshizaki, T. Kishimoto, and K. I. Akamatsu, “Anti-interleukin 6 receptor antibody inhibits murine AA-amyloidosis,” Journal of Rheumatology, vol. 31, no. 6, pp. 1132–1138, 2004. View at Google Scholar · View at Scopus
  25. J. L. Flynn and J. Chan, “Immunology of tuberculosis,” Annual Review of Immunology, vol. 19, pp. 93–129, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. M. Okada, M. Kitahara, S. Kishimoto, T. Matsuda, T. Hirano, and T. Kishimoto, “IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells,” Journal of Immunology, vol. 141, no. 5, pp. 1543–1549, 1988. View at Google Scholar · View at Scopus
  27. F. Tanaka, M. Abe, T. Akiyoshi et al., “The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the interleukin-6 gene using adenovirus vector,” Cancer Research, vol. 57, no. 7, pp. 1335–1343, 1997. View at Google Scholar · View at Scopus
  28. N. V. Serbina, V. Lazarevic, and J. L. Flynn, “CD4+ T cells are required for the development of cytotoxic CD8 T cells during Mycobacterium tuberculosis infection,” Journal of Immunology, vol. 167, no. 12, pp. 6991–7000, 2001. View at Google Scholar · View at Scopus
  29. C. G. Feng, M. Kaviratne, A. G. Rothfuchs et al., “NK cell-derived IFN-γ differentially regulates innate resistance and neutrophil response in T cell-deficient hosts infected with Mycobacterium tuberculosis,” Journal of Immunology, vol. 177, no. 10, pp. 7086–7093, 2006. View at Google Scholar · View at Scopus
  30. K. Saito, T. Yajima, S. Kumabe et al., “Impaired protection against Mycobacterium bovis bacillus Calmette-Guérin infection in IL-15-deficient mice,” Journal of Immunology, vol. 176, no. 4, pp. 2496–2504, 2006. View at Google Scholar · View at Scopus
  31. J. J. Endsley, M. A. Endsley, and D. Mark Estes, “Bovine natural killer cells acquire cytotoxic/effector activity following activation with IL-12/15 and reduce Mycobacterium bovis BCG in infected macrophages,” Journal of Leukocyte Biology, vol. 79, no. 1, pp. 71–79, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. A. Cruz, S. A. Khader, E. Torrado et al., “Cutting edge: IFN-γ regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection,” Journal of Immunology, vol. 177, no. 3, pp. 1416–1420, 2006. View at Google Scholar · View at Scopus
  33. K. I. Happel, E. A. Lockhart, C. M. Mason et al., “Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs,” Infection and Immunity, vol. 73, no. 9, pp. 5782–5788, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. I. E. A. Flesch and S. H. E. Kaufmann, “Stimulation of antibacterial macrophage activities by B-cell stimulatory factor 2 (interleukin-6),” Infection and Immunity, vol. 58, no. 1, pp. 269–271, 1990. View at Google Scholar · View at Scopus
  35. J. L. Flynn, J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, and B. R. Bloom, “An essential role for interferon γ in resistance to Mycobacterium tuberculosis infection,” Journal of Experimental Medicine, vol. 178, no. 6, pp. 2249–2254, 1993. View at Publisher · View at Google Scholar · View at Scopus
  36. I. Garcia, Y. Miyazaki, G. Marchal, W. Lesslauer, and P. Vassalli, “High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-γ in the differentiation of protective granulomas,” European Journal of Immunology, vol. 27, no. 12, pp. 3182–3190, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. A. Zganiacz, M. Santosuosso, J. Wang et al., “TNF-α is a critical negative regulator of type 1 immune activation during intracellular bacterial infection,” Journal of Clinical Investigation, vol. 113, no. 3, pp. 401–413, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. B. M. Saunders, A. A. Frank, I. M. Orme, and A. M. Cooper, “Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection,” Infection and Immunity, vol. 68, no. 6, pp. 3322–3326, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Kindler, A. P. Sappino, G. E. Grau, P. F. Piguet, and P. Vassalli, “The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection,” Cell, vol. 56, no. 5, pp. 731–740, 1989. View at Google Scholar · View at Scopus
  40. P. A. Tessier, P. H. Naccache, I. Clark-Lewis, R. P. Gladue, K. S. Neote, and S. R. McColl, “Chemokine networks in vivo: involvement of C-X-C and C-C chemokines in neutrophil extravasation in vivo in response to TNF-α,” Journal of Immunology, vol. 159, no. 7, pp. 3595–3602, 1997. View at Google Scholar · View at Scopus
  41. M. Kopf, H. Baumann, G. Freer et al., “Impaired immune and acute-phase responses in interleukin-6-deficient mice,” Nature, vol. 368, no. 6469, pp. 339–342, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. S. A. Dalrymple, L. A. Lucian, R. Slattery et al., “Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia,” Infection and Immunity, vol. 63, no. 6, pp. 2262–2268, 1995. View at Google Scholar · View at Scopus
  43. L. Romani, A. Mencacci, E. Cenci et al., “Impaired neutrophil response and CD4 T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans,” Journal of Experimental Medicine, vol. 183, no. 4, pp. 1345–1355, 1996. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Mihara, N. Takagi, Y. Takeda, and Y. Ohsugi, “IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice,” Clinical and Experimental Immunology, vol. 112, no. 3, pp. 397–402, 1998. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Katsume, H. Saito, Y. Yamada et al., “Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice,” Cytokine, vol. 20, no. 6, pp. 304–311, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Kita, T. Tanaka, S. Yoshida et al., “Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model,” Vaccine, vol. 23, no. 17-18, pp. 2132–2135, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. G. P. Walsh, E. V. Tan, E. C. dela Cruz et al., “The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease,” Nature Medicine, vol. 2, no. 4, pp. 430–436, 1996. View at Publisher · View at Google Scholar · View at Scopus